Health · Pharma & Biotech · 8 hrs ago
China approves Eli Lilly's GLP-1 weight-loss pill
China approved Eli Lilly's orforglipron, the first GLP-1 weight-loss pill cleared for sale in the country.
The US drugmaker says the pill is marketed as Foundayo in the United States.
Until now, China had approved GLP-1 treatments for weight management only as injections.
These medicines mimic a gut hormone to curb appetite and regulate blood sugar.
The approval gives Lilly an early lead over Danish rival Novo Nordisk, whose application for an oral version of Wegovy has been accepted but is still awaiting a decision.
Lilly says it is working toward a commercial launch and will supply the pill to authorized healthcare and pharmaceutical institutions.
The pill adds a new option in China's growing market, where obesity treatment sales could reach 30 billion yuan in five to seven years, according to a J.P. Morgan forecast.
Chinese regulators have approved Eli Lilly’s orforglipron, making it the first GLP-1 weight-loss pill cleared in the country.
The decision was announced on Thursday and gives Lilly an early advantage over Danish rival Novo Nordisk in China.
Until now, Chinese regulators had approved GLP-1 medicines for weight management only as injections.
Lilly said it was working to advance the pill’s commercial launch in China and would supply authorized healthcare and pharmaceutical institutions.
The pill will compete with injectable treatments from Lilly, Novo Nordisk, Pfizer and Innovent Biologics, as well as other oral medicines seeking approval.
- Who
- Eli Lilly received approval from Chinese regulators.
- What
- China approved Lilly’s GLP-1 weight-loss pill, orforglipron.
- When
- Thursday; the article was published on November 12, 2026.
- Where
- China.
- Why
- Not stated.
This story does not have two clearly opposing sides.
Novo Nordisk said its application to sell its oral Wegovy in China had been accepted.
Chinese regulators announced approval of Lilly’s orforglipron.
- Drug
- Orforglipron
- Company
- Eli Lilly
- Market
- China
- Approval status
- First GLP-1 weight-loss pill cleared by Chinese regulators
- Publication date
- November 12, 2026